Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer

14 Dec 2010

Abstract excerpt

β-Thalassemia major results from severely reduced or absent expression of the β-chain of adult hemoglobin (α₂β₂;HbA). Increased levels of fetal hemoglobin (α₂γ₂;HbF), such as occurs with hereditary persistence of HbF, ameliorate the severity of β-thalassemia, raising the potential for genetic therapy directed at enhancing HbF. We used an in vitro model of human erythropoiesis to assay for enhanced production of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hemoglobinopathies and Related Disorders
Share to Iron Metabolism and Disorders
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21156846
DOI: 10.1182/blood-2010-08-300723

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transferPMID 21156846Read ↗

Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in vitro and in vivoSemantic proximity Read ↗

Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector.Semantic proximity Read ↗

Editing the core region in HPFH deletions alters fetal and adult globin expression for treatment of β-hemoglobinopathiesSemantic proximity Read ↗

Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated PerspectiveSemantic proximity Read ↗

Editing the core region in HPFH deletions alters fetal and adult globin expression for treatment of β-hemoglobinopathiesSemantic proximity Read ↗

Molecular genetics of β-thalassemiaSemantic proximity Read ↗

Combined approaches for increasing fetal hemoglobin (HbF) and de novo production of adult hemoglobin (HbA) in erythroid cells from β-thalassemia patients: treatment with HbF inducers and CRISPR-Cas9 based genome editingSemantic proximity Read ↗

A combined approach for β-thalassemia based on gene therapy-mediated adult hemoglobin (HbA) production and fetal hemoglobin (HbF) inductionSemantic proximity Read ↗

A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.Semantic proximity Read ↗

In vivo activation of the human δ-globin gene: the therapeutic potential in β-thalassemic mice.Semantic proximity Read ↗

Gene Therapy for Hemoglobinopathies: Tremendous Successes and Remaining CaveatsSemantic proximity Read ↗

Targeting fetal hemoglobin expression to treat β hemoglobinopathiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.